Max W Sung, MD

Clinical Focus

• Chemotherapy
• Colon Cancer
• Colorectal Cancer
• Esophageal Cancer
• Liver Cancer
• Pancreatic Cancer
• Stomach Cancer

• Chemotherapy
• Colon Cancer
• Colorectal Cancer
• Esophageal Cancer
• Liver Cancer
• Pancreatic Cancer
• Stomach Cancer

Research

Locations

Ruttenberg Treatment Center

1470 Madison Avenue, 3rd Floor, New York, NY, 10029

212-241-6756

Insurance Information

Accepted insurance may vary by the doctor’s office location. Please contact the office directly to obtain the most up-to-date insurance information.

Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).

Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.

Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.

Publications

Scopus h-index:24

Article:47

Review Article:4

Comment/Debate:2

Letter:1

Chapter:1

Recent Artifacts

• Molecular Markers of Response to Anti-PD1 Therapy in Advanced Hepatocellular Carcinoma
• Comparative assessment of standard and immune response criteria for evaluation of response to PD-1 monotherapy in unresectable HCC
• Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial
• Baseline Liver Function and Subsequent Outcomes in the Phase 3 REFLECT Study of Patients with Unresectable Hepatocellular Carcinoma
• Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial
• Safety and efficacy of lenvatinib by starting dose based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT
• Morphology of tumor and nontumor tissue in liver resection specimens for hepatocellular carcinoma following nivolumab therapy
• A Drosophila platform identifies a novel, personalized therapy for a patient with adenoid cystic carcinoma
• Mutations in circulating tumor DNA predict primary resistance to systemic therapies in advanced hepatocellular carcinoma
• Safety and Efficacy of Locoregional Treatment during Immunotherapy with Nivolumab for Hepatocellular Carcinoma: A Retrospective Study of 41 Interventions in 29 Patients

Industry Relationships

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Dr. Sung did not report having any of the following types of financial relationships with industry during 2022 and/or 2023: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.